Biosimilar Switching Studies, Human Factors Analyses Are Flashpoints For Industry

US FDA should offer more flexibility on endpoint in clinical switching studies for interchangeability, generic companies say in comments that also argue a draft guidance recommendation for human factors studies to compare use error rates between products is misplaced.